Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel



Status:Completed
Conditions:Contraception
Therapuetic Areas:Reproductive
Healthy:No
Age Range:18 - 35
Updated:11/19/2017
Start Date:April 2011
End Date:June 2014

Use our guide to learn which trials are right for you!

A Multicenter, Open-Label, Randomized Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel

This is a research study of a new experimental vaginal gel known as a spermicide, a birth
control method that kills sperm. This spermicide, called Amphora™, is being compared to a
commercially available spermicide called Conceptrol®, which contains nonoxynol 9; commonly
abbreviated as N-9. Conceptrol® can help prevent pregnancy. This study will determine if this
product prevents pregnancy when inserted into the vagina before intercourse.

Clinical Trial Design

This is a multicenter, open-label, randomized, controlled, Phase III study of repeated use of
Amphora™ gel compared to Conceptrol® Vaginal Gel as the method of contraception over seven
cycles of use. In addition, there is an opportunity for Amphora™ gel subjects to continue
with study treatment for up to 13 cycles of treatment upon completion of the first seven
cycles of treatment.

A subset of subjects (Amphora™ gel and Conceptrol® Vaginal Gel) will undergo colposcopy at
the Admission Visit and at the visits after Cycles 1, 3, and 7 (Treatment Exit). Subjects
participating for 13 cycles will also undergo colposcopy after Cycles 10 and 13. Colposcopic
photographs will be taken at all visits independent of presence of any suspicious areas. Any
suspicious areas and clinical findings will be recorded on the colposcopy case report form.
The colposcopy evaluator for the subset will be blinded regarding the treatment group of the
subject. If at any time during the study the investigator deems colposcopy necessary,
colposcopy will be performed on any subject and will not be limited to subjects in the
colposcopy subset.

A subset of subjects (Amphora™ gel and Conceptrol® Vaginal Gel) will also have
semi-quantitative cultures for E. coli and clinical yeast performed at the Admission Visit
and after Cycles 1, 3, and 7 (Treatment Exit) Visits. Subjects participating for 13 cycles
will also undergo the assessments after Cycles 10 and 13. Another subgroup will have
quantitative vaginal cultures performed after Cycles 1 and 7 (Treatment Exit) Visits, and
also after Cycle 13 for subjects participating in the extension.

Selected research centers will also recruit subjects into the subset of women 36-45 years of
age at enrollment.

Inclusion Criteria:

- Be healthy women, who are sexually active, at risk for pregnancy, and desiring
contraception.

- Be within the age range of 18 through 35 (inclusive) at enrollment if not in the
subset of women with an age of 36-45 at enrollment (age subset at select sites).

- Be at low-risk for both human immunodeficiency virus (HIV) and sexually transmitted
disease (STD) infection and currently have a single sex partner (≥ 4 months) who is
also at low-risk for both HIV and STD infection.

- Have a negative urine pregnancy test prior to enrollment.

- Have normal cyclic menses with a usual length of 21 to 40 days over the last two
cycles or at least one spontaneous, normal menstrual cycle (two menses) since
delivery, abortion, or after discontinuing hormonal contraception/hormonal therapy.

- Be willing to accept a risk of pregnancy.

- Be willing to engage in at least two acts of heterosexual vaginal intercourse per
cycle.

- Be willing to be randomized to either study treatment.

- Be willing to use the study product as the only method of contraception over the
course of the study (with the exception of emergency contraception (EC)), when
indicated).

- Be capable of using the study product properly and agree to observe all study
directions and requirements.

- Be willing to keep a daily diary to record coital information, product use
information, information about the use of other vaginal products, and sign and symptom
data for both the subject and her partner.

- Agree not to participate in any other clinical trials during the course of the study
with the exception of enrolling in the Amphora™ gel extension study.

- Be willing to give written informed consent to participate in the trial.

Exclusion Criteria:

- Have a history of allergy or sensitivity to spermicides or products containing N-9
(nonoxynol-9).

- Have had three or more urinary tract infections (UTIs) in the past year.

- Have a UTI by urine culture, symptomatic yeast vaginitis, or symptomatic bacterial
vaginosis diagnosed by wet mount unless treated and proof of cure is documented.

- Have a history of any recurrent vaginal infections/disorders (either less than or
equal to four times in the past year or less than or equal to three times in the
previous six months).

- Be pregnant, have a suspected pregnancy, or desire to become pregnant during the
course of the study.

- Have a history of infertility or of conditions that may lead to infertility, without
subsequent intrauterine pregnancy.

- Have any contraindications to pregnancy (medical condition) or chronic use of
medications for which significant evidence of fetal risk exists.

- Have had more than one sexual partner in the last four months.

- Have shared injection drug needles in the past unless has a negative HIV test at least
six weeks since last use.

- Have or have been suspected to have HIV infection.

- Have been diagnosed with genital herpes simplex virus (HSV), with the first occurrence
(initial episode) within three months prior to screening.

- Have three or more outbreaks of HSV within the last year.

- Have evidence of Chlamydia trachomatis or Neisseria gonorrhoeae unless she and her
partner complete treatment and proof of cure is documented.

- Have been diagnosed with any other STDs in the six months prior to the Randomization
Visit (with the exception of human papillomavirus (HPV), trichomonas, gonorrhea, adn
Chlamydia).

- Be lactating or breastfeeding.

- Have any clinically significant abnormal vaginal bleeding or spotting within the month
prior to screening.

- Have any clinically significant abnormal finding on pelvic examination or baseline
labs, which in the view of the investigator, precludes her from participating in the
trial.

- Have clinically significant signs of vaginal or cervical irritation on pelvic
examination.

- Have had vaginal or cervical biopsy or vaginal surgery within three months prior to
screening (with the exception of cervical biopsies performed for eligibility
determination).

- Have used vaginal or systemic antibiotics or antifungals within 14 days prior to
screening or enrollment/randomization, with the exception of systemic antibiotics
taken for a UTI and trichomonas diagnosed at screening. Subjects should not have used
systemic antibiotics prescribed at the Screening Visit for a UTI within seven days of
the enrollment/randomization visit.

- Have had a Depo-Provera® injection in the ten months prior to enrollment.

- Have an abnormal Pap test based on the following criteria:

- Pap test in the past 15 months with ASC-US unless:

- less than 21 years of age;

- a repeat Pap test at least six months later was normal;

- reflex HPV testing was performed and was negative for high-risk HPV; or

- a colposcopy (with or without biopsy) found no evidence of dysplasia requiring
treatment or treatment was performed and follow-up at least six months after the
treatment showed no evidence of disease;

- Pap test in the past 15 months with LSIL unless:

- less than 21 years of age;

- a colposcopy (with or without biopsy) found no evidence of dysplasia requiring
treatment or treatment was performed and follow-up at least six months after the
treatment showed no evidence of disease;

- Pap test in the past 15 months with ASC-H, atypical glandular cells, or HSIL unless
colposcopy and/or treatment was performed and follow-up at least six months after the
colposcopy and/or treatment showed no evidence of disease;

- Pap test in the past 15 months with malignant cells.

- Consume (on average) greater than three drinks of an alcoholic beverage per day.

- Have a past history (within 12 months) or current history which, in the PI's judgment,
constitutes of drug abuse (recreational, prescription, or over-the-counter (OTC)).

- Have taken an investigational drug or used an investigational device within the past
30 days.

- Have issues or concerns (in the judgment of the investigator) that may compromise the
safety of the subject or confound the reliability of compliance and information
acquired in this study.

In addition, in order to be eligible to participate in the trial, potential subjects must
state that, to her best knowledge, her sexual partner meets the following criteria:

- Is not infertile.

- Has had untreated chlamydia or gonorrhea in the past six months.

- Has not had more than one sexual partner in the past four months.

- Has no history of allergy or sensitivity to spermicides or products containing N-9.

- Has not been previously diagnosed with or suspected of HIV infection unless he has
subsequently had a negative HIV test.

- Has not been known to have engaged in homosexual intercourse in the past five years
unless he has had negative HIV test results since then.

- Has not shared injection drug needles in the past unless he has had a negative HIV
test at least six weeks since last use.
We found this trial at
42
sites
Cleveland, Ohio 44302
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
5920 Saratoga Blvd
Corpus Christi, Texas 78414
361-906-9178
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
1201 E. 17th Ave
Denver, Colorado 80218
303-298-0222
?
mi
from
Denver, CO
Click here to add this to my saved trials
4671 S. Congress Ave.
Lake Worth, Florida 33461
561-641-0404
?
mi
from
Lake Worth, FL
Click here to add this to my saved trials
1045 East 3900 South
Salt Lake City, Utah 84124
801-261-2000
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
1709 S Rock Rd
Wichita, Kansas 67207
316-689-6629
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Anaheim, California 92801
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
1085 N Harbor Blvd
Anaheim, California 92801
(714) 774-7777
Anaheim Clinical Trials, LLC Anaheim Clinical Trials (ACT) is a research center of excellence for...
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Baltimore, Maryland 21211
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Berkeley, California 94710
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Birmingham, Alabama 35235
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bradenton, Florida
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials
860 Peachwood Drive
DeLand, Florida 32720
?
mi
from
DeLand, FL
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
Houston, Texas 77054
?
mi
from
Houston, TX
Click here to add this to my saved trials
Idaho Falls, Idaho 83404
?
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Irving, Texas 75062
?
mi
from
Irving, TX
Click here to add this to my saved trials
Kazan, Republic Tatarstan 42001
?
mi
from
Kazan,
Click here to add this to my saved trials
Las Vegas, Nevada 89106
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Los Angeles, California 90010
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90010
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida
?
mi
from
Miami, FL
Click here to add this to my saved trials
New Bern, North Carolina 28562
?
mi
from
New Bern, NC
Click here to add this to my saved trials
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
North Miami, Florida 33161
?
mi
from
North Miami, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19114
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97227
?
mi
from
Portland, OR
Click here to add this to my saved trials
3100 Duraleigh Rd
Raleigh, North Carolina 27612
(919) 781-2514
Wake Research Associates, LLC Wake Research is an Organization of Unified Investigational Sites working closely...
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Saint Petersburg, Florida 33709
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
San Diego, California 92123
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Seattle, Washington 98105
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Stamford, Connecticut 06095
?
mi
from
Stamford, CT
Click here to add this to my saved trials
West Palm Beach, Florida 33409
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials